Copyright © 2008 Holly J. Clarke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. W. S. Aronow, P. R. Harding, M. Khursheed, J. S. Vangrow, and N. P. Papageorge's, “Effect of halofenate on serum uric acid,” Clinical Pharmacology & Therapeutics, vol. 14, no. 3, pp. 371–373, 1973.
2. W. S. Aronow, P. R. Harding, M. Khursheed, J. S. Vangrow, N. P. Papageorge's, and J. Mays, “Effect of halofenate on serum lipids,” Clinical Pharmacology & Therapeutics, vol. 14, no. 3, pp. 358–365, 1973.
3. W. S. Aronow, J. Vangrow, J. Pagano, M. Khemka, M. Vawter, and N. P. Papageorge's, “Long-term effect of halofenate on serum lipids,” Current Therapeutic Research: Clinical and Experimental, vol. 16, no. 9, pp. 897–903, 1974.
4. W. S. Aronow, J. S. Vangrow, W. H. Nelson, et al., “Halofenate: an effective hypolipemia- and hypouricemia-inducing drug,” Current Therapeutic Research: Clinical and Experimental, vol. 15, no. 12, pp. 902–906, 1973.
5. W. S. Aronow, M. D. Vicario, K. Moorthy, J. King, M. Vawter, and N. P. Papageorge's, “Long-term efficacy of halofenate on serum triglyceride levels,” Current Therapeutic Research: Clinical and Experimental, vol. 18, no. 6, pp. 855–861, 1975.
6. C. A. Dujovne, D. L. Azarnoff, P. Pentikainen, C. Manion, A. Hurwitz, and K. Hassanein, “A two-year crossover therapeutic trial with halofenate and clofibrate,” The American Journal of the Medical Sciences, vol. 272, no. 3, pp. 277–284, 1976. View at Publisher · View at Google Scholar
7. E. B. Feldman, F. B. Gluck, and A. C. Carter, “Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia,” The Journal of Clinical Pharmacology, vol. 18, no. 5-6, pp. 241–248, 1978.
8. L. H. Krut, H. C. Seftel, and B. I. Joffe, “Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia,” South African Medical Journal, vol. 51, no. 11, pp. 348–352, 1977.
9. A. K. Jain, J. R. Ryan, and F. G. McMahon, “Potentiation of hypoglycemic effect of sulfonylureas by halofenate,” The New England Journal of Medicine, vol. 293, no. 25, pp. 1283–1286, 1975.
10. E. A. Kohl, J. A. Magner, S. T. Persellin, G. M. Vaughan, D. J. Kudzma, and S. J. Friedberg, “Improved control of non-insulin-dependent diabetes mellitus by combined halofenate and chlorpropamide therapy,” Diabetes Care, vol. 7, no. 1, pp. 19–24, 1984. View at Publisher · View at Google Scholar
11. D. J. Kudzma and S. J. Friedberg, “Potentiation of hypoglycemic effect of chlorpropamide and phenformin by halofenate,” Diabetes, vol. 26, no. 4, pp. 291–295, 1977. View at Publisher · View at Google Scholar
12. T. Allen, F. Zhang, S. A. Moodie, et al., “Halofenate is a selective peroxisome proliferator-activated receptor $\gamma$ modulator with antidiabetic activity,” Diabetes, vol. 55, no. 9, pp. 2523–2533, 2006. View at Publisher · View at Google Scholar · View at PubMed
13. F. Zhang, B. E. Lavan, and F. M. Gregoire, “Selective modulators of PPAR-$\gamma$ activity: molecular aspects related to obesity and side-effects,” PPAR Research, vol. 2007, Article ID 32696, 7 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
14. P. A. Krieter, A. E. Colletti, G. A. Doss, and R. R. Miller, “Disposition and metabolism of the hypoglycemic agent pioglitazone in rats,” Drug Metabolism and Disposition, vol. 22, no. 4, pp. 625–630, 1994.
15. Z. J. Lin, D. Desai-Krieger, and L. Shum, “Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry,” Journal of Chromatography B, vol. 801, no. 2, pp. 265–272, 2004. View at Publisher · View at Google Scholar
16. P. Yi, C. E. Hadden, W. F. Annes, et al., “The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor $\alpha$-$\gamma$ dual, $\gamma$-dominant agonist in mice, rats, and monkeys,” Drug Metabolism and Disposition, vol. 35, no. 1, pp. 51–61, 2007. View at Publisher · View at Google Scholar · View at PubMed
17. M. D. Greenspan, J. I. Germershausen, and R. Mackow, “Effect of halofenate and clofibrate on lipid synthesis in rat adipocytes,” Biochimica et Biophysica Acta, vol. 380, no. 2, pp. 190–198, 1975.
18. W. D. Wosilait and P. Nagy, “The distribution of halofenate in plasma: a comparative analysis using Scatchard vs. stepwise association constants,” Research Communications in Chemical Pathology and Pharmacology, vol. 14, no. 1, pp. 75–81, 1976.
19. R. L. Rich, Y. S. N. Day, T. A. Morton, and D. G. Myszka, “High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE,” Analytical Biochemistry, vol. 296, no. 2, pp. 197–207, 2001. View at Publisher · View at Google Scholar · View at PubMed
20. Y. S. N. Day and D. G. Myszka, “Characterizing a drug's primary binding site on albumin,” Journal of Pharmaceutical Sciences, vol. 92, no. 2, pp. 333–343, 2003. View at Publisher · View at Google Scholar · View at PubMed
21. J. M. Collins and R. W. Klecker, Jr., “Evaluation of highly bound drugs: interspecies, intersubject, and related comparisons,” The Journal of Clinical Pharmacology, vol. 42, no. 9, pp. 971–975, 2002.